Clinical Report: Hiatus Hernia's Role in Barrett’s Oesophagus Development and Management

Overview

Hiatus hernia (HH) is strongly associated with the development of Barrett’s oesophagus (BO), especially with larger hernia sizes and long-segment BO. Evidence suggests HH may influence progression to dysplasia and malignancy and impair treatment efficacy, particularly radiofrequency ablation.

Background

Barrett’s oesophagus is a premalignant condition that can progress to oesophageal adenocarcinoma. Hiatus hernia is frequently observed in patients with BO and is thought to contribute to its pathogenesis by promoting gastro-oesophageal reflux. Despite this, HH is not formally recognized as a major risk factor in international clinical guidelines. Understanding the role of HH in BO development, progression, and treatment outcomes is critical for improving patient management.

Data Highlights

Key Findings

• Hiatus hernia is strongly linked to the onset of Barrett’s oesophagus, particularly with hernias larger than 2–4 cm.
• Long-segment Barrett’s oesophagus shows a higher association with the presence of hiatus hernia.
• There is a possible trend towards increased dysplastic and malignant progression of BO in patients with HH, though evidence is inconsistent.
• Hiatus hernia may reduce the efficacy of radiofrequency ablation, with larger hernias requiring more treatment sessions.
• Surgical repair of HH may benefit selected asymptomatic patients with hernias ≥4 cm and established BO by restoring normal anatomy and reducing reflux.

Clinical Implications

Clinicians should consider hiatus hernia size when assessing risk and management strategies for patients with Barrett’s oesophagus. Larger hernias may warrant closer surveillance and consideration of surgical intervention to improve treatment outcomes. The potential impact of HH on ablation efficacy suggests that tailored therapeutic approaches may be necessary.

Conclusion

Current evidence supports hiatus hernia as a significant risk factor for Barrett’s oesophagus development, with implications for disease progression and treatment response. Further research is needed to clarify its role in malignant progression and optimize management strategies.

References

1. Shaheen NJ et al. 2022 -- Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline
2. Lord RV 2003 -- Antireflux surgery for Barrett’s oesophagus
3. Wilson H et al. 2022 -- Fundoplication is superior to medical therapy for Barrett’s esophagus disease regression and progression
4. Tsoi EH et al. 2020 -- Factors that predict a poor response to radiofrequency ablation for Barrett’s oesophagus with dysplasia
5. Papaefthymiou A et al. 2024 -- Efficacy and Safety of Cryoablation in Barrett’s Esophagus and Comparison with Radiofrequency Ablation: A Meta-Analysis